

**Publikationen 2015 – Klinik für Gastroenterologie u. Hepatologie**

- (1) Anastasiou, O.; Sydor, S.; Sowa, J. P.; Manka, P.; Katsounas, A.; Syn, W. K.; Fuhrer, D.; Gieseler, R. K.; Bechmann, L. P.; Gerken, G.; Moeller, L. C.; Canbay, A. Higher Thyroid-Stimulating Hormone, Triiodothyronine and Thyroxine Values Are Associated With Better Outcome in Acute Liver Failure. *PLoS One* **2015**, *10*, e0132189.
- (2) Beilfuss, A.; Sowa, J. P.; Sydor, S.; Beste, M.; Bechmann, L. P.; Schlattjan, M.; Syn, W. K.; Wedemeyer, I.; Mathe, Z.; Jochum, C.; Gerken, G.; Gieseler, R. K.; Canbay, A. Vitamin D Counteracts Fibrogenic TGF-Beta Signalling in Human Hepatic Stellate Cells Both Receptor-Dependently and Independently. *Gut* **2015**, *64*, 791-799.
- (3) Best, J.; Zahn, A.; Beilfuss, A.; Sydor, S.; Fingas, C.; Sowa, J. P.; Anastasiou, O.; Cicinnati, V.; Gerken, G.; Canbay, A.; Bechmann, L. P. Mycophenolic Acid Induces Apoptosis of Hepatic Stellate Cells in an in Vitro Model of HCV. *Ann. Hepatol.* **2015**, *14*, 396-403.
- (4) Blomeyer, S.; Tyczynski, B.; Gerken, G.; Canbay, A. [Diagnosis and Therapy of the Hepatorenal Syndrome]. *Dtsch. Med. Wochenschr.* **2015**, *140*, 1083-1090.
- (5) Casper, M.; Mengel, M.; Fuhrmann, C.; Herrmann, E.; Appenrodt, B.; Schiedermaier, P.; Reichert, M.; Bruns, T.; Engelmann, C.; Grunhage, F.; Lammert, F. The INCA Trial (Impact of NOD2 Genotype-Guided Antibiotic Prevention on Survival in Patients With Liver Cirrhosis and Ascites): Study Protocol for a Randomized Controlled Trial. *Trials* **2015**, *16*, 83.
- (6) Dechene, A.; Kodde, C.; Kathemann, S.; Treckmann, J.; Lainka, E.; Paul, A.; Gerken, G.; Feldstein, A. E.; Hoyer, P. F.; Canbay, A. Endoscopic Treatment of Pediatric Post-Transplant Biliary Complications Is Safe and Effective. *Dig. Endosc.* **2015**, *27*, 505-511.
- (7) El, F. A.; Ertle, J.; El, D. A.; Shaker, M. K.; Dechene, A.; Abdella, H.; Mueller, S.; Barakat, E.; Lauenstein, T.; Bockisch, A.; Gerken, G.; Schlaak, J. F. In Intermediate Stage Hepatocellular Carcinoma: Radioembolization With Yttrium 90 or Chemoembolization? *Liver Int.* **2015**, *35*, 627-635.
- (8) Feld, J. J.; Jacobson, I. M.; Hezode, C.; Asselah, T.; Ruane, P. J.; Gruener, N.; Abergel, A.; Mangia, A.; Lai, C. L.; Chan, H. L.; Mazzotta, F.; Moreno, C.; Yoshida, E.; Shafran, S. D.; Towner, W. J.; Tran, T. T.; McNally, J.; Osinusi, A.; Svarovskaia, E.; Zhu, Y.; Brainard, D. M.; McHutchison, J. G.; Agarwal, K.; Zeuzem, S. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. *N. Engl. J. Med.* **2015**, *373*, 2599-2607.
- (9) Foster, G. R.; Afdhal, N.; Roberts, S. K.; Brau, N.; Gane, E. J.; Pianko, S.; Lawitz, E.; Thompson, A.; Shiffman, M. L.; Cooper, C.; Towner, W. J.; Conway, B.; Ruane, P.; Bourliere, M.; Asselah, T.; Berg, T.; Zeuzem, S.; Rosenberg, W.; Agarwal, K.; Stedman, C. A.; Mo, H.; Dvory-Sobol, H.; Han, L.; Wang, J.; McNally, J.; Osinusi, A.; Brainard, D. M.; McHutchison, J. G.; Mazzotta, F.; Tran, T. T.; Gordon, S. C.; Patel, K.; Reau, N.; Mangia, A.; Sulkowski, M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. *N. Engl. J. Med.* **2015**, *373*, 2608-2617.

- (10) Frank, M.; Hennenberg, E. M.; Eyking, A.; Runzi, M.; Gerken, G.; Scott, P.; Parkhill, J.; Walker, A. W.; Cario, E. TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine. *J. Immunol.* **2015**, *194*, 1983-1995.
- (11) Gruner, N.; Viazov, S.; Korn, K.; Knoll, A.; Trippler, M.; Schlaak, J. F.; Gerken, G.; Roggendorf, M.; Ross, R. S. Performance Characteristics of the VERSANT Hepatitis C Virus RNA 1.0 (KPCR) Assay. *Int. J. Med. Microbiol.* **2015**, *305*, 627-635.
- (12) Hahnemann, M. L.; Nensa, F.; Kinner, S.; Kohler, J.; Gerken, G.; Umutlu, L.; Lauenstein, T. C. Quantitative Assessment of Small Bowel Motility in Patients With Crohn's Disease Using Dynamic MRI. *Neurogastroenterol. Motil.* **2015**, *27*, 841-848.
- (13) Hahnemann, M. L.; Nensa, F.; Kinner, S.; Maderwald, S.; Umutlu, L.; Gerken, G.; Lauenstein, T. C. Improved Detection of Inflammatory Bowel Disease by Additional Automated Motility Analysis in Magnetic Resonance Imaging. *Invest Radiol.* **2015**, *50*, 67-72.
- (14) Hahnemann, M. L.; Nensa, F.; Kinner, S.; Gerken, G.; Lauenstein, T. C. Motility Mapping As Evaluation Tool for Bowel Motility: Initial Results on the Development of an Automated Color-Coding Algorithm in Cine MRI. *J. Magn Reson. Imaging* **2015**, *41*, 354-360.
- (15) Herzer, K.; Papadopoulos-Kohn, A.; Achterfeld, A.; Canbay, A.; Piras-Straub, K.; Paul, A.; Walker, A.; Timm, J.; Gerken, G. Management of Telaprevir-Based Triple Therapy for Hepatitis C Virus Recurrence Post Liver Transplant. *World J. Hepatol.* **2015**, *7*, 1287-1296.
- (16) Herzer, K.; Papadopoulos-Kohn, A.; Walker, A.; Achterfeld, A.; Paul, A.; Canbay, A.; Timm, J.; Gerken, G. Daclatasvir, Simeprevir and Ribavirin As a Promising Interferon-Free Triple Regimen for HCV Recurrence After Liver Transplant. *Digestion* **2015**, *91*, 326-333.
- (17) Herzer, K.; Gerken, G. Hepatitis C Virus Reinfection After Liver Transplant: New Chances and New Challenges in the Era of Direct-Acting Antiviral Agents. *World J. Hepatol.* **2015**, *7*, 532-538.
- (18) Hoyo-Becerra, C.; Liu, Z.; Yao, J.; Kaltwasser, B.; Gerken, G.; Hermann, D. M.; Schlaak, J. F. Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-Alpha-Related Depression in Hepatitis C Virus Infection. *Mol. Neurobiol.* **2015**, *52*, 318-329.
- (19) Kalsch, J.; Bechmann, L. P.; Heider, D.; Best, J.; Manka, P.; Kalsch, H.; Sowa, J. P.; Moebus, S.; Slomiany, U.; Jockel, K. H.; Erbel, R.; Gerken, G.; Canbay, A. Normal Liver Enzymes Are Correlated With Severity of Metabolic Syndrome in a Large Population Based Cohort. *Sci. Rep.* **2015**, *5*, 13058.
- (20) Kefalakes, H.; Budeus, B.; Walker, A.; Jochum, C.; Hilgard, G.; Heinold, A.; Heinemann, F. M.; Gerken, G.; Hoffmann, D.; Timm, J. Adaptation of the Hepatitis B Virus Core Protein to CD8(+) T-Cell Selection Pressure. *Hepatology* **2015**, *62*, 47-56.
- (21) Kefalakes, H.; Jochum, C.; Hilgard, G.; Kahraman, A.; Bohrer, A. M.; El, H. N.; Heinemann, F. M.; Verheyen, J.; Gerken, G.; Roggendorf, M.; Timm, J. Decades After Recovery From Hepatitis B and HBsAg Clearance the CD8+ T Cell Response Against HBV Core Is Nearly Undetectable. *J. Hepatol.* **2015**, *63*, 13-19.
- (22) Manka, P.; Bechmann, L. P.; Coombes, J. D.; Thodou, V.; Schlattjan, M.; Kahraman, A.; Syn, W. K.; Saner, F.; Gerken, G.; Baba, H.; Verheyen, J.; Timm, J.; Canbay, A.

- Hepatitis E Virus Infection As a Possible Cause of Acute Liver Failure in Europe. *Clin. Gastroenterol Hepatol.* **2015**, *13*, 1836-1842.
- (23) Papadopoulos-Kohn, A.; Achterfeld, A.; Paul, A.; Canbay, A.; Timm, J.; Jochum, C.; Gerken, G.; Herzer, K. Daily Low-Dose Tacrolimus Is a Safe and Effective Immunosuppressive Regimen During Telaprevir-Based Triple Therapy for Hepatitis C Virus Recurrence After Liver Transplant. *Transplantation* **2015**, *99*, 841-847.
- (24) Piras-Straub, K.; Khairzada, K.; Gerken, G.; Saner, F.; Treckmann, J.; Paul, A.; Canbay, A.; Herzer, K. Glutamate Dehydrogenase and Alkaline Phosphatase As Very Early Predictors of Hepatocellular Carcinoma Recurrence After Liver Transplantation. *Digestion* **2015**, *91*, 117-127.
- (25) Piras-Straub, K.; Khairzada, K.; Trippler, M.; Baba, H. A.; Kaiser, G. M.; Paul, A.; Canbay, A.; Weber, F.; Gerken, G.; Herzer, K. TRAIL Expression Levels in Human Hepatocellular Carcinoma Have Implications for Tumor Growth, Recurrence and Survival. *Int. J. Cancer* **2015**, *136*, E154-E160.
- (26) Rathmayer, M.; Scheffer, H.; Braun, M.; Heinlein, W.; Akoglu, B.; Brechmann, T.; Golder, S. K.; Lankisch, T.; Messmann, H.; Schneider, A.; Wagner, M.; Flessa, S.; Meier, A.; Lewerenz, B.; Gossner, L.; Faiss, S.; Toerner, T.; Werner, T.; Wilke, M. H.; Lerch, M. M.; Schepp, W. [Improvement of Cost Allocation in Gastroenterology by Introduction of a Novel Service Catalogue Covering the Complete Spectrum of Endoscopic Procedures]. *Z Gastroenterol* **2015**, *53*, 183-198.
- (27) Schelhorn, J.; Best, J.; Reinboldt, M. P.; Gerken, G.; Ruhlmann, M.; Lauenstein, T. C.; Antoch, G.; Kinner, S. Therapy Response Assessment After Radioembolization of Patients With Hepatocellular Carcinoma--Comparison of MR Imaging With Gadolinium Ethoxybenzyl Diethylenetriamine Penta-Acetic Acid and Gadobutrol. *J. Vasc. Interv. Radiol.* **2015**, *26*, 972-979.
- (28) Schelhorn, J.; Best, J.; Reinboldt, M. P.; Dechene, A.; Gerken, G.; Ruhlmann, M.; Lauenstein, T. C.; Antoch, G.; Kinner, S. Does Diffusion-Weighted Imaging Improve Therapy Response Evaluation in Patients With Hepatocellular Carcinoma After Radioembolization? Comparison of MRI Using Gd-EOB-DTPA With and Without DWI. *J. Magn Reson. Imaging* **2015**, *42*, 818-827.
- (29) Schieber, K.; Lindner, M.; Sowa, J. P.; Gerken, G.; Scherbaum, N.; Kahraman, A.; Canbay, A.; Erim, Y. Self-Reports on Symptoms of Alcohol Abuse: Liver Transplant Patients Versus Rehabilitation Therapy Patients. *Prog. Transplant* **2015**, *25*, 203-209.
- (30) Tan, S.; Vollmar, N.; Benson, S.; Sowa, J. P.; Bechmann, L. P.; Gerken, G.; Fuhrer, D.; Canbay, A. Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves Under Metformin Treatment in Polycystic Ovary Syndrome. *Int. J. Endocrinol.* **2015**, *2015*, 254169.
- (31) Theysohn, J. M.; Ruhlmann, M.; Muller, S.; Dechene, A.; Best, J.; Haubold, J.; Umutlu, L.; Gerken, G.; Bockisch, A.; Lauenstein, T. C. Radioembolization With Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts? *PLoS One* **2015**, *10*, e0137587.
- (32) Werner, M.; Driftmann, S.; Kleinehr, K.; Kaiser, G. M.; Mathe, Z.; Treckmann, J. W.; Paul, A.; Skibbe, K.; Timm, J.; Canbay, A.; Gerken, G.; Schlaak, J. F.; Broering, R. All-In-One: Advanced Preparation of Human Parenchymal and Non-Parenchymal Liver Cells. *PLoS One* **2015**, *10*, e0138655.

- 
- (33) Zeuzem, S.; Flisiak, R.; Vierling, J. M.; Mazur, W.; Mazzella, G.; Thongsawat, S.; Abdurakhmanov, D.; Van, K. N.; Calistru, P.; Heo, J.; Stanciu, C.; Gould, M.; Makara, M.; Hsu, S. J.; Buggisch, P.; Samuel, D.; Mutimer, D.; Nault, B.; Merz, M.; Bao, W.; Griffel, L. H.; Brass, C.; Naoumov, N. V. Randomised Clinical Trial: Alisporivir Combined With Peginterferon and Ribavirin in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection (ESSENTIAL II). *Aliment. Pharmacol. Ther.* **2015**, *42*, 829-844.
- (34) Zhu, A. X.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Chung, H. C.; Baron, A. D.; Pfiffer, T. E.; Okusaka, T.; Kubackova, K.; Trojan, J.; Sastre, J.; Chau, I.; Chang, S. C.; Abada, P. B.; Yang, L.; Schwartz, J. D.; Kudo, M. Ramucirumab Versus Placebo As Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): a Randomised, Double-Blind, Multicentre, Phase 3 Trial. *Lancet Oncol.* **2015**, *16*, 859-870.